Since activation through TLR9 ligands and type I IFN is a characteristic feature of lupus B cells, these results suggest that targeting glutaminolysis may reduce plasmablast differentiation and autoantibody production in SLE. Here, TLR9 is linked to systemic lupus erythematosus.